According to Onyx Pharmaceuticals, researchers participating in ongoing phase II trials of Onyx - 015 in different cancer types, including colorectal and pancreatic cancer, have observed a response to therapy in some patients. (ucsf.edu)
And results presented at the conference from ongoing phase 1 and 2 trials showed that 38 of 50 patients treated with the drug had seen their tumours shrink to some degree. (scienceblog.cancerresearchuk.org)
Ongoing Phase 1b / 2 clinical trials combine entinostat with KEYTRUDA ® from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ ® from Genentech, Inc. for triple negative breast cancer; and with BAVENCIO ® from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. (wistar.org)